Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 22:9:639233.
doi: 10.3389/fcell.2021.639233. eCollection 2021.

Cell-Free DNA: Hope and Potential Application in Cancer

Yan-Yan Yan  1   2 , Qiao-Ru Guo  2   3 , Feng-Hua Wang  4 , Rameshwar Adhikari  5 , Zhuang-Yan Zhu  1 , Hai-Yan Zhang  1 , Wen-Min Zhou  2 , Hua Yu  6 , Jing-Quan Li  3 , Jian-Ye Zhang  1   2   3
Affiliations
Review

Cell-Free DNA: Hope and Potential Application in Cancer

Yan-Yan Yan et al. Front Cell Dev Biol. .

Abstract

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA in various areas of cancer management are attracting attention. In this review article, we discuss the potential relevance of using cfDNA analysis in clinical oncology, particularly in cancer screening, early diagnosis, therapeutic evaluation, monitoring disease progression; and determining disease prognosis.

Keywords: cancer; cell-free DNA (cfDNA); diagnosis; liquid biopsy; therapeutic effect evaluation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The applications of cfDNA in cancer.
See this image and copyright information in PMC

References

    1. Agostini M., Pucciarelli S., Enzo M. V., Del Bianco P., Briarava M., Bedin C., et al. . (2011). Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann. Surg. Oncol. 18, 2461–2468. 10.1245/s10434-011-1638-y - DOI - PubMed
    1. Ai B., Liu H., Huang Y., Peng P. (2016). Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 7, 44583–44595. 10.18632/oncotarget.10069 - DOI - PMC - PubMed
    1. Almodovar K., Iams W. T., Meador C. B., Zhao Z., York S., Horn L., et al. . (2018). Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse. J. Thorac. Oncol. 13, 112–123. 10.1016/j.jtho.2017.09.1951 - DOI - PMC - PubMed
    1. Alunni-Fabbroni M., Ronsch K., Huber T., Cyran C. C., Seidensticker M., Mayerle J., et al. . (2019). Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J. Transl. Med. 17:328. 10.1186/s12967-019-2079-9 - DOI - PMC - PubMed
    1. Anker P., Lefort F., Vasioukhin V., Lyautey J., Lederrey C., Chen X. Q., et al. . (1997). K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology. 112, 1114–1120. 10.1016/s0016-5085(97)70121-5 - DOI - PubMed